Profiling EGFR in Triple Negative Breast Tumor Using Affibody PET Imaging
Profiling EGFR in Triple Negative Breast Tumor Using Affibody PET Imaging
出处
《国际放射医学核医学杂志》
2016年第5期329-337,共9页
International Journal of Radiation Medicine and Nuclear Medicine
关键词
乳腺癌
治疗方法
临床分析
医学研究
Affibody
Epidermal grown factor receptor
Positron-emission tomography
Triplenegative breast heoplasms
Copper radioisotopes
参考文献35
-
1Jernal A, Siegel R, Xu J, et al. Cancer Statistics, 2010[J]. CA Can- cer J Clin, 2010,60(5): 277-300. DOI: 10.3322/caac.20073.
-
2Turner NC, Jones AL. Management of breast cancer--Part II [J]. BMJ, 2008, 337: a540. DOI: 10.1136/bmj.a540.
-
3Turner NC, Jones AL. Management of breast cancer--part I [J]. BMJ, 2008, 337: a421. DOI: 10.1136/bmj.a421.
-
4Valabrega G, Montemurro F, Aglietta M. Trastuzumab: mechanism of action, resistance and future perspectives in HER2-overexpress- ing breast cancer[J]. Ann Oneol, 2007, 18(6): 977-984.
-
5Hatake K, Tokudome N, Ito Y. Next generation molecular targeted agents for breast cancer: focus on EGFR and VEGFR pathways[J]. Breast Cancer, 2007, 14(2): 132-149.
-
6Cameron DA, Stein S. Drug Insight: intraeellular inhibitors of HER2--clinical development of lapatinib in breast cancer[J]. Nat Clin Pract Oneol, 2008, 5(9): 512-520. DOI: lO.1038/neponc1156.
-
7Nielsen TO, Hsu FD, Jensen K, et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma[J]. Clin Cancer Res, 2004, 10(16): 5367-5374. DOI: 10. 1158/1078-0432.CCR-04-0220.
-
8Hynes NE, Lane HA. ERBB receptors and cancer: the complexity of targeted inhibitors[J]. Nat Rev Cancer, 2005, 5(5): 341-354. DOI: 10. 1038/nre 1609.
-
9Hynes ME, MacDonald G. ErbB receptors and signaling pathways in cancer[J]. Curr Opin Cell Biol, 2009, 21(2): 177-184. DOI: 10. 1016/j.eeb.2008.12.010.
-
10Corkery B, Crown J, Clynes M, et al. Epidermal growth factor re- ceptor as a potential therapeutic target in triple-negative breast can- cer[J]. Ann Oneol, 2009, 20(5): 862-867. DOI: 10.1093/annonc/ mdn710.
-
1朱鸿静,张春梅,杨清,陈广业,周仕娴,李敏.三阴性乳腺癌及其研究进展[J].国际检验医学杂志,2014,35(17):2350-2352. 被引量:4
-
2李瑞卿,张元梅,王书山,丁继强,周心怡,周长杰.卡培他滨长期维持治疗三阴性乳腺癌1例[J].临床肿瘤学杂志,2016,21(5):474-475. 被引量:4
-
3刘新兰,马慧,段瑜,刘媛媛.三阴型乳腺癌的临床病理特征和预后分析[J].宁夏医学杂志,2015,37(7):579-581. 被引量:7
-
4倪新初,孙苏平.乳腺癌的分子亚型及治疗策略研究进展[J].癌症进展,2009,7(4):422-426. 被引量:4
-
5许丽娟,刘彤,杨建杰,刘凤阁,崔莉,胡艳萍,刘辉,李新飞.三阴性乳腺癌与基底细胞样乳腺癌临床病理分析[J].实用癌症杂志,2010,25(1):62-64. 被引量:9
-
6郑健,张雪鹏.微小RNA在三阴性乳腺癌中的研究进展[J].华北理工大学学报(医学版),2016,18(6):499-504. 被引量:3
-
7王昇,张宁妹,刘奇伦,马薇春.267例浸润性乳腺癌分子亚型的临床病理特点分析[J].宁夏医科大学学报,2011,33(11):1036-1039. 被引量:1
-
8洪雷,魏素菊,邢晓英,刘义冰,贾明.三阴乳腺癌患者259例临床病理特征及预后分析[J].实用医学杂志,2013,29(15):2526-2528. 被引量:13
-
9李庆霞,邢雅军,赵静,颜聪亚,张秀智,荀文娟.乳腺浸润性导管癌分子分型与临床特征的关系[J].肿瘤防治研究,2013,40(4):341-344. 被引量:13
-
10高逸冰,徐锋,傅点,程文,高建平,张征宇,葛京平.膀胱尿路上皮癌长链非编码RNA差异表达及意义[J].中华实验外科杂志,2013,30(12):2517-2520. 被引量:4